Review Article
Year: 2022 | Month: July-September | Volume: 7 | Issue: 3 | Pages: 92-100
DOI: https://doi.org/10.52403/ijshr.20220715
The Advantage Efficacy of Intranasal Live-Attenuated Vaccine Against SARS-CoV-2
Ratthaphum Sae-ngow
Assumption College Nakhonratchasima, Nai Mueang, Nakhon Ratchasima, Thailand, 30000
ABSTRACT
Coronavirus disease 2019 (COVID-19) has ushered in a new era of breakthrough infections. The SARS-CoV-2 virus, which causes COVID-19, emerged in late 2019 in a seafood market in Wuhan, China, and was linked to pneumonia-associated sickness, which can culminate in respiratory failure. COVID-19 can potentially cause cardiovascular and gastrointestinal diseases and indicate an inflammatory condition. Regarding the diminishing protective immunity of vaccinations over time and the urgency of vaccine-evading SARS-CoV-2 variations, it is recommended that a booster injection be administered, and the research of variant-specific vaccines is continuing. As a result of the COVID-19 pandemic, vaccine development became a focal point of global research. However, vaccine development necessitates considerable time. Between preclinical research and the final vaccine's commercialisation, years or more than a decade are often required. Several options for SARS-CoV-2 vaccines have begun clinical trials globally after months of research and development. As stipulated by the WHO, vaccine development must involve preclinical research, clinical application, clinical trial agency application, registered clinical trial, phase I clinical trial, phase II clinical trial, phase III clinical trial, marketing, and manufacture of the vaccine. It is essential to create a balanced list of the benefits and drawbacks of deploying LAVs so that a well-informed choice can be made on which LAVs may be dispatched promptly to prevent and manage unanticipated pandemic breakouts.
Keywords: Intranasal live-attenuated vaccine, Covid-19 vaccine, SAR-CoV-2